Alnylam Pharmaceuticals, Inc.
MODIFIED DOUBLE STRANDED OLIGONUCLEOTIDE
Last updated:
Abstract:
One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions.
Status:
Application
Type:
Utility
Filling date:
5 Nov 2019
Issue date:
16 Dec 2021